Copyright © 2009 Arno Sungarian et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

1. E. C. Burton and M. D. Prados, “Malignant gliomas,” Current Treatment Options in Oncology, vol. 1, no. 5, pp. 459–468, 2000. View at Scopus
2. H. Gal, A. Makovitzki, N. Amariglio, G. Rechavi, Z. Ram, and D. Givol, “A rapid assay for drug sensitivity of glioblastoma stem cells,” Biochemical and Biophysical Research Communications, vol. 358, no. 3, pp. 908–913, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
3. P. Kleihues, D. N. Louis, B. W. Scheithauer, et al., “The WHO classification of tumors of the nervous system,” Journal of Neuropathology and Experimental Neurology, vol. 61, no. 3, pp. 215–229, 2002. View at Scopus
4. D. R. Macdonald, “Temozolomide for recurrent high-grade glioma,” Seminars in Oncology, vol. 28, no. 4, supplement 13, pp. 3–12, 2001. View at Scopus
5. M. D. Prados and V. Levin, “Biology and treatment of malignant glioma,” Seminars in Oncology, vol. 27, no. 3, supplement 6, pp. 1–10, 2000. View at Scopus
6. C. Nieder, A. L. Grosu, and M. Molls, “A comparison of treatment results for recurrent malignant gliomas,” Cancer Treatment Reviews, vol. 26, no. 6, pp. 397–409, 2000. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
7. M. Napolitano, F. Keime-Guibert, A. Monjour, et al., “Treatment of supratentorial glioblastoma multiforme with radiotherapy and a combination of BCNU and tamoxifen: a phase II study,” Journal of Neuro-Oncology, vol. 45, no. 3, pp. 229–235, 1999. View at Publisher · View at Google Scholar · View at Scopus
8. C. Dazzi, A. Cariello, M. Giannini, et al., “A sequential chemo-radiotherapeutic treatment for patients with malignant gliomas: a phase II pilot study,” Anticancer Research, vol. 20, no. 1B, pp. 515–518, 2000. View at Scopus
9. M. F. Back, E. L. L. Ang, W.-H. Ng, et al., “Improved median survival for glioblastoma multiforme following introduction of adjuvant temozolomide chemotherapy,” Annals of the Academy of Medicine Singapore, vol. 36, no. 5, pp. 338–342, 2007. View at Scopus
10. A. R. Dix, W. H. Brooks, T. L. Roszman, and L. A. Morford, “Immune defects observed in patients with primary malignant brain tumors,” Journal of Neuroimmunology, vol. 100, no. 1-2, pp. 216–232, 1999. View at Publisher · View at Google Scholar · View at Scopus
11. W. Roth and M. Weller, “Chemotherapy and immunotherapy of malignant glioma: molecular mechanisms and clinical perspectives,” Cellular and Molecular Life Sciences, vol. 56, no. 5-6, pp. 481–506, 1999. View at Publisher · View at Google Scholar · View at Scopus
12. A. Sablotzki, H. Ebel, J. Muhling, et al., “Dysregulation of immune response following neurosurgical operations,” Acta Anaesthesiologica Scandinavica, vol. 44, no. 1, pp. 82–87, 2000. View at Publisher · View at Google Scholar · View at Scopus
13. A. Billich, “Thymosin $\alpha$1. SciClone Pharmaceuticals,” Current Opinion in Investigational Drugs, vol. 3, no. 5, pp. 698–707, 2002. View at Scopus
14. B. Bodey, “Thymic hormones in cancer diagnostics and treatment,” Expert Opinion on Biological Therapy, vol. 1, no. 1, pp. 93–107, 2001. View at Scopus
15. B. Bodey, B. Bodey Jr., S. E. Siegel, and H. E. Kaiser, “Review of thymic hormones in cancer diagnosis and treatment,” International Journal of Immunopharmacology, vol. 22, no. 4, pp. 261–273, 2000. View at Publisher · View at Google Scholar · View at Scopus
16. P. Andreone, C. Cursaro, A. Gramenzi, et al., “In vitro effect of thymosin-$\alpha$1 and interferon-$\alpha$ on Th1 and Th2 cytokine synthesis in patients with chronic hepatitis C,” Journal of Viral Hepatitis, vol. 8, no. 3, pp. 194–201, 2001. View at Publisher · View at Google Scholar · View at Scopus
17. W. Y. Attia, M. Badamchian, A. L. Goldstein, and B. L. Spangelo, “Thymosin stimulates interleukin-6 production from rat spleen cells in vitro,” Immunopharmacology, vol. 26, no. 2, pp. 171–179, 1993. View at Scopus
18. C. N. Baxevanis, S. Frillingos, K. Seferiadis, et al., “Enhancement of human T lymphocyte function by prothymosin $\alpha$: increased production of interleukin-2 and expression of interleukin-2 receptors in normal human peripheral blood T lymphocytes,” Immunopharmacology and Immunotoxicology, vol. 12, no. 4, pp. 595–617, 1990. View at Scopus
19. C. N. Baxevanis, A. D. Gritzapis, G. V. Z. Dedoussis, N. G. Papadopoulos, O. Tsolas, and M. Papamichail, “Induction of lymphokine-activated killer activity in mice by prothymosin $\alpha$,” Cancer Immunology Immunotherapy, vol. 38, no. 4, pp. 281–286, 1994. View at Scopus
20. J. Beuth, J. M. Schierholz, and G. Mayer, “Thymosin $\alpha$1 application augments immune response and down-regulates tumor weight and organ colonization in BALB/c-mice,” Cancer Letters, vol. 159, no. 1, pp. 9–13, 2000. View at Publisher · View at Google Scholar · View at Scopus
21. O. J. Cordero, C. S. Sarandeses, J. L. Lopez, and M. Nogueira, “Prothymosin $\alpha$ enhances human natural killer cell cytotoxicity: role in mediating signals for NK activity,” Lymphokine and Cytokine Research, vol. 11, no. 5, pp. 277–285, 1992. View at Scopus
22. F. Garbin, K. Eckert, P. Immenschuh, E. D. Kreuser, and H. R. Maurer, “Prothymosin $\alpha$1 effects, in vitro, on the antitumor activity and cytokine production of blood monocytes from colorectal tumor patients,” International Journal of Immunopharmacology, vol. 19, no. 6, pp. 323–332, 1997. View at Publisher · View at Google Scholar · View at Scopus
23. A. P. Knutsen, J. J. Freeman, K. R. Mueller, S. T. Roodman, and J. D. Bouhasin, “Thymosin-$\alpha$1 stimulates maturation of CD34⁺ stem cells into CD3⁺4⁺ cells in an in vitro thymic epithelia organ coculture model,” International Journal of Immunopharmacology, vol. 21, no. 1, pp. 15–26, 1999. View at Publisher · View at Google Scholar · View at Scopus
24. B. L. Spangelo, D. D. Farrimond, M. Pompilius, and K.-L. Bowman, “Interleukin-1β and thymic peptide regulation of pituitary and glial cell cytokine expression and cellular proliferation,” Annals of the New York Academy of Sciences, vol. 917, pp. 597–607, 2000. View at Scopus
25. B. L. Spangelo, D. D. Farrimond, M. Thapa, et al., “Thymosin fraction 5 inhibits the proliferation of the rat neuroendocrine MMQ pituitary adenoma and C6 glioma cell lines in vitro,” Endocrinology, vol. 139, no. 4, pp. 2155–2162, 1998. View at Scopus
26. M. Tijerina, W. C. Gorospe, K.-L. Bowman, M. Badamchian, A. L. Goldstein, and B. L. Spangelo, “A novel thymosin peptide stimulates interleukin-6 release from rat C6 glioma cells in vitro,” NeuroImmunoModulation, vol. 4, no. 3, pp. 163–170, 1997. View at Scopus
27. H. L.-Y. Chan, J.-L. Tang, W. Tam, and J. J.-Y. Sung, “The efficacy of thymosin in the treatment of chronic hepatitis B virus infection: a meta-analysis,” Alimentary Pharmacology and Therapeutics, vol. 15, no. 12, pp. 1899–1905, 2001. View at Publisher · View at Google Scholar · View at Scopus
28. R.-N. Chien, C.-Y. Lin, C.-T. Yeh, and Y.-F. Liaw, “Hepatitis B virus genotype B is associated with better response to thymosin $\alpha$1 therapy than genotype C,” Journal of Viral Hepatitis, vol. 13, no. 12, pp. 845–850, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
29. G. Ideo and A. Bellobuono, “New therapies for the treatment of chronic hepatitis C,” Current Pharmaceutical Design, vol. 8, no. 11, pp. 959–966, 2002. View at Scopus
30. G. K. K. Lau, A. Nanji, J. Hou, et al., “Thymosin-$\alpha$1 and famciclovir combination therapy activates T-cell response in patients with chronic hepatitis B virus infection in immune-tolerant phase,” Journal of Viral Hepatitis, vol. 9, no. 4, pp. 280–287, 2002. View at Publisher · View at Google Scholar · View at Scopus
31. M. Saruc, H. Yuceyar, N. Kucukmetin, M. A. Demir, and A. R. Kandiloglu, “Combination thymosin-$\alpha$1 and interferon-$\alpha$2b in the treatment of anti-HBe-positive chronic hepatitis B in Turkey,” Hepato-Gastroenterology, vol. 49, no. 45, pp. 798–802, 2002. View at Scopus
32. K. E. Sherman, C. C. Jones, A. L. Goldstein, and P. H. Naylor, “Low thymosin $\alpha$-1 concentrations in patients chronically infected with the hepatitis B virus,” Viral Immunology, vol. 4, no. 3, pp. 195–199, 1991. View at Scopus
33. K. E. Sherman, M. Sjogren, R. L. Creager, et al., “Combination therapy with thymosin $\alpha$1 and interferon for the treatment of chronic hepatitis C infection: a randomized, placebo-controlled double-blind trial,” Hepatology, vol. 27, no. 4, pp. 1128–1135, 1998. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
34. A. Gramenzi, C. Cursaro, P. Andreone, and M. Bernardi, “Thymalfasin: clinical pharmacology and antiviral applications,” BioDrugs, vol. 9, no. 6, pp. 477–486, 1998. View at Publisher · View at Google Scholar · View at Scopus
35. E. Garaci, F. Pica, G. Rasi, and C. Favalli, “Thymosin $\alpha$ 1 in the treatment of cancer: from basic research to clinical application,” International Journal of Immunopharmacology, vol. 22, no. 12, pp. 1067–1076, 2000. View at Publisher · View at Google Scholar · View at Scopus
36. S. M. Ji, L. S. Li, Q. Q. Sun, J. S. Chen, G. Z. Sha, and Z. H. Liu, “Immunoregulation of thymosin $\alpha$ 1 treatment of cytomegalovirus infection accompanied with acute respiratory distress syndrome after renal transplantation,” Transplantation Proceedings, vol. 39, no. 1, pp. 115–119, 2007.
37. B. Wang, F. He, Y. Lin, M. Huang, and S. F. Zhou, “Effect of recombinant human thymosin-$\alpha 1$, an immuno-modulating peptide with 28 amino acids, on the activity of cytochrome P450s,” Drug Metabolism Letters, vol. 1, no. 3, pp. 199–204, 2007. View at Publisher · View at Google Scholar · View at Scopus
38. S. M. de La Monte, N. Ganju, and J. R. Wands, “Microtiter immunocytochemical ELISA assay,” BioTechniques, vol. 26, no. 6, pp. 1073–1078, 1999. View at Scopus
39. S. M. de la Monte, T. R. Neely, J. Cannon, and J. R. Wands, “Ethanol impairs insulin-stimulated mitochondrial function in cerebellar granule neurons,” Cellular and Molecular Life Sciences, vol. 58, no. 12-13, pp. 1950–1960, 2001. View at Scopus
40. H.-J. Ochel, “Correlation between crystal violet dissolution assay and manual colony counting on the in vitro effects of Hsp90-inhibitors,” Journal of Experimental Therapeutics and Oncology, vol. 5, no. 1, pp. 9–13, 2005. View at Scopus
41. S. M. de la Monte, S. A. Lahousse, J. Carter, and J. R. Wands, “ATP luminescence-based motility-invasion assay,” BioTechniques, vol. 33, no. 1, pp. 98–106, 2002. View at Scopus
42. J. E. Davis, V. R. Sutton, M. J. Smyth, and J. A. Trapani, “Dependence of granzyme B-mediated cell death on a pathway regulated by Bcl-2 or its viral homology, BHRF1,” Cell Death and Differentiation, vol. 7, no. 10, pp. 973–983, 2000. View at Scopus
43. M. Hayashida, H. Kawano, T. Nakano, K. Shiraki, and A. Suzuki, “Cell death induction by CTL: perforin/granzyme B system dominantly acts for cell death induction in human hepatocellular carcinoma cells,” Proceedings of the Society for Experimental Biology and Medicine, vol. 225, no. 2, pp. 143–150, 2000. View at Scopus
44. K. Kontani, S. Sawai, J. Hanaoka, N. Tezuka, S. Inoue, and S. Fujino, “Involvement of granzyme B and perforin in suppressing nodal metastasis of cancer cells in breast and lung cancers,” European Journal of Surgical Oncology, vol. 27, no. 2, pp. 180–186, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
45. M. E. Pipkin and J. Lieberman, “Delivering the kiss of death: progress on understanding how perforin works,” Current Opinion in Immunology, vol. 19, no. 3, pp. 301–308, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
46. M. M. Simon, P. Waring, M. Lobigs, et al., “Cytotoxic T cells specifically induce Fas on target cells, thereby facilitating exocytosis-independent induction of apoptosis,” Journal of Immunology, vol. 165, no. 7, pp. 3663–3672, 2000. View at Scopus
47. D. Vermijlen, C. J. Froelich, D. Luo, N. Suarez-Huerta, B. Robaye, and E. Wisse, “Perforin and granzyme B induce apoptosis in FasL-resistant colon carcinoma cells,” Cancer Immunology, Immunotherapy, vol. 50, no. 4, pp. 212–217, 2001. View at Publisher · View at Google Scholar · View at Scopus
48. N. L. Vujanovic, “Role of TNF family ligands in antitumor activity of natural killer cells,” International Reviews of Immunology, vol. 20, no. 3-4, pp. 415–437, 2001. View at Scopus
49. P. S. Sepe, S. A. Lahousse, B. Gemelli, et al., “Role of the aspartyl-asparaginyl-beta-hydroxylase gene in neuroblastoma cell motility,” Laboratory Investigation, vol. 82, no. 7, pp. 881–891, 2002.
50. C. N. Baxevanis, C. Sfagos, E. Anastasopoulos, G. J. Reclos, and M. Papamichail, “Prothymosin-$\alpha$ enhances HLA-DR antigen expression on monocytes from patients with multiple sclerosis,” Journal of Neuroimmunology, vol. 27, no. 2-3, pp. 141–147, 1990. View at Scopus
51. C. N. Baxevanis, G. J. Reclos, M. Economou, et al., “Mechanism of action of prothymosin $\alpha$ in the human autologous mixed lymphocyte response,” Immunopharmacology and Immunotoxicology, vol. 10, no. 4, pp. 443–461, 1988. View at Scopus
52. C. N. Baxevanis, G. J. Reclos, C. Panneerselvam, and M. Papamichail, “Enhancement of human T lymphocyte functions by prothymosin $\alpha$. I. Augmentation of mixed lymphocyte culture reactions and soluble protein-induced proliferative responses,” Immunopharmacology, vol. 15, no. 2, pp. 73–84, 1988. View at Scopus
53. P. Di Francesco, F. Pica, S. Marini, C. Favalli, and E. Garaci, “Thymosin $\alpha$ one restores murine T-cell-mediated responses inhibited by in vivo cocaine administration,” International Journal of Immunopharmacology, vol. 14, no. 1, pp. 1–9, 1992. View at Scopus
54. J. Hsia, N. Sarin, J. H. Oliver, and A. L. Goldstein, “Aspirin and thymosin increase interleukin-2 and interferon-$\gamma$ production by human peripheral blood lymphocytes,” Immunopharmacology, vol. 17, no. 3, pp. 167–173, 1989. View at Scopus
55. M. B. Sztein and S. A. Serrate, “Characterization of the immunoregulatory properties of thymosin $\alpha$ 1 on interleukin-2 production and interleukin-2 receptor expression in normal human lymphocytes,” International Journal of Immunopharmacology, vol. 11, no. 7, pp. 789–800, 1989. View at Scopus
56. A. K. Hall, “Liarozole amplifies retinoid-induced apoptosis in human prostate cancer cells,” Anti-Cancer Drugs, vol. 7, no. 3, pp. 312–320, 1996. View at Scopus
57. O. V. Markova, A. G. Evstafieva, S. E. Mansurova, et al., “Cytochrome c is transformed from anti- to pro-oxidant when interacting with truncated oncoprotein prothymosin $\alpha$,” Biochimica et Biophysica Acta, vol. 1557, no. 1–3, pp. 109–117, 2003. View at Publisher · View at Google Scholar · View at Scopus
58. R. K. Naz, P. Kaplan, M. Badamchian, and A. L. Goldstein, “Effects of synthetic thymosin-$\alpha$1 and its analogs on fertilizability of human sperm: search for a biologically active, stable epitope,” Archives of Andrology, vol. 35, no. 1, pp. 63–69, 1995. View at Scopus
59. R. K. Naz, A. C. Menge, and A. Sacco, “Treatment with thymosin $\alpha$-1 increases fertilizing capacity of sperm of infertile men: a multicenter trial,” Archives of Andrology, vol. 35, no. 2, pp. 149–154, 1995. View at Scopus